Pages that link to "Item:Q4670477"
From MaRDI portal
The following pages link to Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities (Q4670477):
Displayed 34 items.
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach (Q93669) (← links)
- Incoherent dose-escalation in phase I trials using the escalation with overdose control approach (Q725696) (← links)
- Stochastic approximation and modern model-based designs for dose-finding clinical trials (Q903289) (← links)
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials (Q903293) (← links)
- Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials (Q1929691) (← links)
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes (Q2057378) (← links)
- A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering (Q2170396) (← links)
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity (Q2441853) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- Cumulative cohort design for dose-finding (Q2455719) (← links)
- A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients (Q2861803) (← links)
- Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes (Q2861956) (← links)
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial (Q2931051) (← links)
- Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology (Q3078865) (← links)
- Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials (Q3078908) (← links)
- On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance (Q3078934) (← links)
- A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method (Q3079010) (← links)
- Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes (Q3183237) (← links)
- Joint modelling of recurrence and progression of adenomas: a latent variable approach (Q3413103) (← links)
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
- Risk-Group-Specific Dose Finding Based on an Average Toxicity Score (Q3576932) (← links)
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities (Q4670477) (← links)
- Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (Q5050425) (← links)
- Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment (Q5051094) (← links)
- Impact of different model structure and prior distribution in continual reassessment method (Q5087922) (← links)
- The adaptive accelerated biased coin design for phase I clinical trials (Q5124969) (← links)
- Ethical issues in oncology biostatistics (Q5424159) (← links)
- A weighted zero-inflated Poisson model for estimation of recurrence of adenomas (Q5425035) (← links)
- Dynamic Comparison of Kaplan–Meier Proportions: Monitoring a Randomized Clinical Trial with a Long‐Term Binary Endpoint (Q5450474) (← links)
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent (Q5714615) (← links)
- Target toxicity design for phase I dose-finding (Q5880075) (← links)
- DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses (Q6068878) (← links)
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)